Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT002, a Novel Bispecific IL-4Rα/IL-5 Antibody: Results From the Single- and Multiple-ascending Dose Healthy Volunteers Portions of a Phase I Study

BBT002 - Bambusa Therapeutics

https://ats2026.d365.events/education/abstracts/abstracts/84799b24-b387-404f-826a-43328a8d0417

Wei Liang, PhD; Lisa Li, MD; Jingjing Jiang, M.D., Ph.D.; Shanshan Xu, M.D., Ph.D.; Lara Hatchuel, MD; Johnathan Lee, MD; Yu Chen, M.D., Ph.D.; Thang Ho, PhD

Mar 3, 2026